Ocugen’s Countdown to 2027: Regulatory Path Clears as Cash Runway Extends, but Stock Remains Stuck in Neutral
The clock is ticking for Ocugen, and the market is counting every second. The biotech group now has a clear European regulatory pathway for its gene therapy OCU400 — the...